FIELD: medicine.
SUBSTANCE: invention relates to complex immunomodelling treatment of patients with chronic heart failure (CHF). For this purpose to patients with CHF of II-IV functional classes according to NYHA and LV ejection fraction less than 45% at the background of conventional complex therapy, which includes application of diuretics, vasodilatators, cardiac glycosides, inhibitors of angiotensin-converting enzyme, additionally introduced is carvedilol in dose 12.5-50 mg/day. Introduction is performed in two intakes in equal parts for 12 months.
EFFECT: reduction of cytokine activity and syndrome correction of secondary immunodeficiency, which reduces severity of tissue affection and improves microcirculation and central hemodynamics, reduction of CHF severity and prevention of heart remodeling in said group of patients.
2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF DIFFERENTIAL PRESCRIPTION OF β-ADRENORECEPTOR BLOCKING AGENTS IN PATIENTS WITH CHRONIC CARDIAC FAILURE | 2010 |
|
RU2454998C1 |
| METHOD OF COMPLEX IMMUNOMODULATING TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTION | 2010 |
|
RU2422136C1 |
| METHOD FOR THE TREATMENT OF CHRONIC HEART FAILURE IN YOUNG CHILDREN WITH A DILATED PHENOTYPE OF CARDIOMYOPATHY | 2021 |
|
RU2768596C1 |
| METHOD OF TREATING PATIENTS SUFFERING CHRONIC CARDIAC FAILURE COMPROMISED TYPE 2 DIABETES | 2010 |
|
RU2421218C1 |
| METHOD FOR PREDICTION OF CLINICAL COURSE OF CHRONIC CARDIAC INSUFFICIENCY IN PATIENTS WITH ISCHEMIC HEART DISEASE | 2014 |
|
RU2599501C1 |
| METHOD FOR REHABILITATION OF ELDERLY PATIENTS WITH ISCHEMIC HEART DISEASES ACCOMPANIED BY CHRONIC HEART INSUFFICIENCY FOLLOWING MYOCARDIAL INFARCTION | 2014 |
|
RU2554756C1 |
| METHOD FOR TREATING CHRONIC HEART FAILURE | 2005 |
|
RU2304964C2 |
| METHOD FOR PREDICTING THE ONE-YEAR RISK OF ADVERSE CARDIOVASCULAR EVENTS IN MEN AFTER DECOMPENSATION OF CHRONIC HEART FAILURE WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION AND OBSTRUCTIVE SLEEP APNEA SYNDROME | 2021 |
|
RU2767266C1 |
| METHOD OF CONTROL OVER EFFICIENCY OF TREATMENT OF PATIENTS SUFFERED FROM ACUTE MYOCARDIAL INFARCTION AND POSTINFARCTION CARDIOSCLEROSIS BY INHIBITORS OF ANGIOTONIN-TRANSFORMING ENZYME | 1997 |
|
RU2147206C1 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF LIFE-THREATENING VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH IN PATIENTS WITH CORONARY HEART DISEASE AND HEART FAILURE WITH A REDUCED EJECTION FRACTION WITHIN 12 MONTHS AFTER IMPLANTATION OF A CARDIOVERTER DEFIBRILLATOR | 2021 |
|
RU2758120C1 |
